Viatris Inc.

The scores point in different directions, and a careful reader should weigh them together. The Beneish M-Score is -3.256, below the -1.78 threshold, so it is not in the elevated manipulation-risk zone. That is a statistical screen that flags unusual patterns in financial statements for closer reading. It is not evidence of manipulation, and it does not clear the company of every accounting question. The Altman Z-Score here is the Z-double-prime variant, which reads 0.65 and falls in the distress zone; this is a statistical screen based on balance sheet and profitability ratios, not a forecast of failure. The Piotroski F-Score is 5 of 9 computable signals, a mixed reading of profitability, leverage and efficiency measures. The balance sheet shows deleveraging: long-term debt fell from $14.04 billion at the end of 2024 to $12.48 billion at the end of 2025, while equity declined from $18.64 billion to $14.71 billion over the same period. Revenue for 2025 fell 3.0% to $14.25 billion. The Q1 2026 adjusted gross margin of 56% compares with a U.S. GAAP gross margin of 33%, a gap driven mainly by $591.5 million of purchase accounting amortization and other related items. Management reports that its top ten products represented about 40% of net sales in Q1 2026, up from 38% a year earlier, which concentrates exposure. The risk factors also tie future revenue to timely new product introductions and R&D programs such as selatogrel and cenerimod. Readers may want to look at how new product growth, the impairment history and the Nashik remediation costs develop in future 10-Q and 10-K filings.

Catalyst.According to the Q1 2026 10-Q MD&A, consolidated total revenues rose 8% to $3.52 billion from $3.25 billion, but only about 3% on a constant currency basis, because favorable currency translation contributed roughly $161.8 million. Management attributes the constant-currency growth to new product sales of approximately $70.7 million, mostly in Developed Markets, and net base business growth of about $34.0 million, mainly in Greater China. Greater China net sales rose 22% as reported and 18% in constant currency, driven by e-commerce, retail and private hospitals. JANZ net sales declined on government price reductions and added competition.

Hidden risk.The 2025 results are far weaker than the Q1 2026 headline. The 10-K shows a 2025 net loss of $3.51 billion and an operating loss of $2.66 billion, and the Q1 2026 MD&A describes a $2.94 billion goodwill impairment recorded in the first quarter of 2025. Operating cash flow of $2.32 billion is positive, so the reported ratio of operating cash flow to net income of -0.66 reflects a negative denominator, not cash generation outpacing earnings. Q1 2026 also carried a $71.9 million write-off from the Nashik fire, an $84.5 million contingent consideration loss, and a $64.9 million loss on Biocon equity shares. The risk factors warn that strategic transactions and new product launches may not deliver their intended benefits.